Alaunos Therapeutics Inc. [NASDAQ: TCRT] gained 8.41% or 0.06 points to close at $0.73 with a heavy trading volume of 4509300 shares. The company report on March 16, 2022 that Alaunos Therapeutics to Report Fourth Quarter and Full Year 2021 Financial Results on March 30, 2022.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free.
Alaunos Therapeutics, Inc. (“Alaunos” or the “Company”) (Nasdaq: TCRT), today announced that it will report financial results for the fourth quarter ended December 31, 2021 on Wednesday, March 30, 2022, before the open of U.S. markets. Following the announcement, the Company will host a conference call and webcast at 8:30 a.m. ET to provide a corporate update and review the financial results.
The conference call can be accessed by dialing 844-309-0618 (United States) or 661-378-9465 (International) with the conference code 9091406. A live webcast may be accessed using the link here, or by visiting the “Investors” section of the Alaunos website at www.alaunos.com. After the live webcast, the event will be archived on the Company’s website for approximately 30 days after the call.
It opened the trading session at $0.66, the shares rose to $0.7263 and dropped to $0.605, the range by which the price of stock traded the whole day. The daily chart for TCRT points out that the company has recorded -57.04% loss over the past six months. However, it is still -17.74% lower than its most recent low trading price.
If we look at the average trading volume of 2.17M shares, TCRT reached to a volume of 4509300 in the most recent trading day, which is why market watchdogs consider the stock to be active.
Here is what top equities market gurus are saying about Alaunos Therapeutics Inc. [TCRT]:
The Average True Range (ATR) for Alaunos Therapeutics Inc. is set at 0.11, with the Price to Sales ratio for TCRT stock in the period of the last 12 months amounting to 391.93. The Price to Book ratio for the last quarter was 2.27, with the Price to Cash per share for the same quarter was set at 0.42.
Trading performance analysis for TCRT stock
Alaunos Therapeutics Inc. [TCRT] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -18.23. With this latest performance, TCRT shares dropped by -12.04% in over the last four-week period, additionally sinking by -57.04% over the last 6 months – not to mention a drop of -82.71% in the past year of trading.
Overbought and oversold stocks can be easily traced with the Relative Strength Index (RSI), where an RSI result of over 70 would be overbought, and any rate below 30 would indicate oversold conditions. An RSI rate of 50 would represent a neutral market momentum. The current RSI for TCRT stock in for the last two-week period is set at 42.96, with the RSI for the last a single of trading hit 42.60, and the three-weeks RSI is set at 43.18 for Alaunos Therapeutics Inc. [TCRT]. The present Moving Average for the last 50 days of trading for this stock 0.8851, while it was recorded at 0.7064 for the last single week of trading, and 1.6475 for the last 200 days.
Alaunos Therapeutics Inc. [TCRT]: A deeper dive into fundamental analysis
Return on Total Capital for TCRT is now -71.07, given the latest momentum, and Return on Invested Capital for the company is -71.23. Return on Equity for this stock declined to -73.04, with Return on Assets sitting at -62.61. When it comes to the capital structure of this company, Alaunos Therapeutics Inc. [TCRT] has a Total Debt to Total Equity ratio set at 3.88. Additionally, TCRT Total Debt to Total Capital is recorded at 3.74, with Total Debt to Total Assets ending up at 3.29. Long-Term Debt to Equity for the company is recorded at 3.22, with the Long-Term Debt to Total Capital now at 3.10.
Reflecting on the efficiency of the workforce at the company, Alaunos Therapeutics Inc. [TCRT] managed to generate an average of -$754,491 per employee.Alaunos Therapeutics Inc.’s liquidity data is similarly interesting compelling, with a Quick Ratio of 3.40 and a Current Ratio set at 3.40.
An analysis of insider ownership at Alaunos Therapeutics Inc. [TCRT]
There are presently around $76 million, or 59.20% of TCRT stock, in the hands of institutional investors. The top three institutional holders of TCRT stocks are: BLACKROCK INC. with ownership of 16,764,972, which is approximately -1.008% of the company’s market cap and around 0.90% of the total institutional ownership; MSD PARTNERS, L.P., holding 15,151,516 shares of the stock with an approximate value of $10.15 million in TCRT stocks shares; and DISCOVERY CAPITAL MANAGEMENT, LLC / CT, currently with $8.94 million in TCRT stock with ownership of nearly 6.376% of the company’s market capitalization.
Positions in Alaunos Therapeutics Inc. stocks held by institutional investors increased at the end of March and at the time of the March reporting period, where 77 institutional holders increased their position in Alaunos Therapeutics Inc. [NASDAQ:TCRT] by around 16,579,929 shares. Additionally, 75 investors decreased positions by around 8,563,824 shares, while 36 investors held positions by with 88,436,269 shares. The mentioned changes placed institutional holdings at 113,580,022 shares, according to the latest SEC report filing. TCRT stock had 26 new institutional investments in for a total of 4,553,227 shares, while 20 institutional investors sold positions of 1,041,280 shares during the same period.